STAT+: All eyes on data on Biogen’s tau therapy

Article excerpt

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Lots happening in London these days, my colleague Andrew Joseph reports: At a pancreatic cancer meeting, researchers were buzzing about the implications of daraxonrasib, and at a major Alzheimer’s meeting, tau therapies are taking center stage. Back here in the U.S., HHS has begun to craft national guidance on safely tapering SSRIs, and the FDA just cleared Sanofi’s wearable injector for a myeloma drug. Continue to STAT+ to read the full story…